Cardiovascular toxicity remains a major cause of concern during preclinical and clinical development as well as contributing to post-approval withdrawal of medicines. This issue is particularly relevant for anticancer drugs where, the significant improvement in the life expectancies of patients has dramatically extended the use and duration of drug therapies. Nevertheless, cardiotoxicity is also observed with other classes of drugs, including antibiotics, antidepressants, and antipsychotics. This article summarizes the clinical manifestations of druginduced cardiotoxicity by various cancer chemotherapies and novel drugs for the treatment of other diseases. Furthermore, it presents on overview of biomarker and imaging techniques for the detection of drug-induced cardiotoxicity. Guidelines for the management of patients exposed to drugs with cardiotoxic potential are presented as well as a checklist for collecting information when a safety signal is observed in clinical trials to more effectively assess the risk of cardiotoxicity and manage patient safety.

Drug attrition during pre-clinical and clinical development : understanding and managing drug-induced cardiotoxicity / N. Ferri, P. Siegl, A. Corsini, J. Herrmann, A. Lerman, R. Benghozi. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 138:3(2013 Jun), pp. 470-484.

Drug attrition during pre-clinical and clinical development : understanding and managing drug-induced cardiotoxicity

N. Ferri
Primo
;
A. Corsini;
2013-06

Abstract

Cardiovascular toxicity remains a major cause of concern during preclinical and clinical development as well as contributing to post-approval withdrawal of medicines. This issue is particularly relevant for anticancer drugs where, the significant improvement in the life expectancies of patients has dramatically extended the use and duration of drug therapies. Nevertheless, cardiotoxicity is also observed with other classes of drugs, including antibiotics, antidepressants, and antipsychotics. This article summarizes the clinical manifestations of druginduced cardiotoxicity by various cancer chemotherapies and novel drugs for the treatment of other diseases. Furthermore, it presents on overview of biomarker and imaging techniques for the detection of drug-induced cardiotoxicity. Guidelines for the management of patients exposed to drugs with cardiotoxic potential are presented as well as a checklist for collecting information when a safety signal is observed in clinical trials to more effectively assess the risk of cardiotoxicity and manage patient safety.
Drug cardiotoxicity; Monitoring cardiotoxicity; Patients management
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
corsini1-s2.0-S0163725813000740-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 476.87 kB
Formato Adobe PDF
476.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/219108
Citazioni
  • ???jsp.display-item.citation.pmc??? 47
  • Scopus 125
  • ???jsp.display-item.citation.isi??? 115
social impact